alpha-factor prepropeptide;
cellular localization;
heterologous production;
human dopamine D-2S receptor;
immunogold electron microscopy;
membrane protein;
P;
pastoris;
processing;
D O I:
10.1080/10606820490279466
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
In order to evaluate the methylotrophic yeast Pichia pastoris as means for high-yield production of homogenous D-2S receptor protein, we have expressed the unmodified D-2S receptor and various D-2S receptor fusion constructs under the transcriptional control of the highly inducible promotor of the P. pastoris alcoholoxidase 1 gene in strain SMD1163. Fusion of the D-2S receptor gene to the alpha-factor preprosequence proved to be essential for receptor production. For the receptor fusion constructs a gene dosage of more than two copies per cell increased production levels three-to sixfold. Adding various dopaminergic ligands to the induction medium increased yields up to tenfold, reaching 51,500 +/- 5700 receptors/ cell. Immunoblot analysis of the effect of tunicamycin on D-2S receptor fusion proteins and immunoprecipitation of metabolically labeled wild-type and glycosylation-deficient D-2S receptor fusion proteins revealed that the high-mannose-type glycosylation of the D-2S receptor prevents cleavage of the alpha-factor prosequence by the Kex2 endopeptidase. Abolishing glycosylation restored correct processing. Immunogold electron microscopy showed that recombinant yeast cells overproducing the D-2S receptor developed membrane stacks harboring the receptor protein. The pharmacological profile of the recombinant D-2S receptor was similar to that reported for neuronal D-2 receptors independent of glycosylation and processing. In conclusion, the D-2S receptor can readily be produced in P. pastoris with high yield suitable for receptor purification and future structural studies.
机构:
Mitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, JapanMitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, Japan
Ohya, T
Ohyama, M
论文数: 0引用数: 0
h-index: 0
机构:
Mitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, JapanMitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, Japan
Ohyama, M
Kobayashi, K
论文数: 0引用数: 0
h-index: 0
机构:
Mitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, JapanMitsubishi Pharma Corp, Prot Res Labs, Div Pharmaceut Res, Hirakata, Osaka, Japan